Abvc Biopharma (ABVC) Short-Term Debt repayments (2015 - 2020)
Abvc Biopharma's (ABVC) quarterly Short-Term Debt repayments came in at -$23757.0 in Q4 2020, down 346.72% YoY from $9629.0 in Q1 2020, and up 16.45% on a QoQ basis from -$28434.0 in Q3 2020.
Abvc Biopharma (ABVC) Short-Term Debt repayments (2015 - 2020) Analysis & Trends
Abvc Biopharma (ABVC) has 3 years of Short-Term Debt repayments data on file, last reported at -$23757.0 in Q4 2020.
- Quarterly Short-Term Debt repayments fell 346.72% year-over-year to -$23757.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was -$42517.0 (changed N/A YoY) and the FY2021 annual result came in at -$23044.0, down 2323.13% from the prior year.
- Short-Term Debt repayments advanced to -$23757.0 in Q4 2020, from -$28434.0 in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of $9629.0 in Q4 2019 to a low of -$28434.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ST Debt Repayment (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -23,757.00 |
| Dec 31, 2020 | -23,757.00 |
| Sep 30, 2020 | -28,434.00 |
| Sep 30, 2020 | -28,434.00 |
| Dec 31, 2019 | 9,629.00 |
| Dec 31, 2019 | 9,629.00 |
| Sep 30, 2019 | 45.00 |
| Sep 30, 2019 | 45.00 |
| Dec 31, 2015 | -7,000.00 |
| Dec 31, 2015 | -7,000.00 |